Esomeprazole: Proton Pump Inhibitor for GERD, Peptic Ulcer and H. pylori
Esomeprazole is the S-enantiomer of omeprazole and belongs to the proton pump inhibitor (PPI) class of acid-suppressive drugs. Like all PPIs, it irreversibly inhibits the H+/K+-ATPase (the proton pump) in the parietal cells of the stomach lining, dramatically reducing gastric acid secretion regardless of the stimulus. It was developed as a pharmacokinetically optimised version of the racemic omeprazole, with greater bioavailability and more predictable acid suppression.
PPIs are among the most widely prescribed drug classes globally. While highly effective, concerns have grown over the years about their long-term use being associated with several nutritional deficiencies and infection risks, prompting guidelines to recommend the lowest effective dose for the shortest necessary duration.
Mechanism of Action
Esomeprazole is a prodrug that is activated in the acidic secretory canaliculi of gastric parietal cells. Activated esomeprazole forms a covalent sulphenamide bond with cysteine residues on the H+/K+-ATPase enzyme, permanently inactivating the proton pump. Since new proton pumps must be synthesised to restore acid secretion, the effect persists for 18 to 24 hours after a single dose despite the short plasma half-life of one to 1.5 hours. Maximal acid suppression develops over several days of regular dosing as the proportion of active proton pumps decreases. Esomeprazole raises gastric pH above four, which is the threshold required for healing of acid-related mucosal lesions and optimal activity of some antibiotics used in H. pylori eradication.
Indications
Esomeprazole is approved for gastro-oesophageal reflux disease (GERD) including erosive oesophagitis and symptomatic GERD; peptic ulcer disease including NSAID-associated ulcers (treatment and prevention); Helicobacter pylori eradication in combination with antibiotics; Zollinger-Ellison syndrome; and prevention of stress ulcers in critically ill patients. It is also used to protect the gastric mucosa during long-term NSAID therapy in high-risk patients.
Dosage and Administration
Standard adult dose for GERD: 20 to 40 mg once daily taken 30 to 60 minutes before breakfast. For erosive oesophagitis: 40 mg once daily for four to eight weeks. For H. pylori eradication: 20 mg twice daily with two antibiotics for seven to fourteen days. Esomeprazole should be taken before eating, as acid secretion is stimulated by food and the proton pumps must be active for PPI absorption and binding. Swallow tablets whole; do not crush. No dose adjustment is required for mild to moderate renal or hepatic impairment; severe hepatic impairment requires dose reduction to 20 mg maximum.
Side Effects
Short-term side effects are mild and include headache, nausea, diarrhoea, abdominal pain, and flatulence, each occurring in one to five percent of patients. Long-term use (beyond eight weeks) is associated with several clinically important adverse effects: hypomagnesaemia (low magnesium) can develop insidiously over months to years, manifesting as muscle cramps, arrhythmias, and seizures, and is not corrected by oral magnesium supplementation in many cases. Vitamin B12 malabsorption occurs with chronic acid suppression, leading to deficiency in long-term users. Bone fracture risk is modestly increased with long-term high-dose PPI use due to impaired calcium absorption. Clostridium difficile infection risk is elevated with PPI use. Community-acquired pneumonia risk is modestly increased, as gastric acid normally kills aspirated bacteria.
Interactions
Esomeprazole significantly reduces the antiplatelet effect of clopidogrel by inhibiting its activation via CYP2C19; the combination is generally discouraged, and pantoprazole is preferred when a PPI is needed alongside clopidogrel. Esomeprazole increases bioavailability of drugs requiring low gastric pH for dissolution and reduces efficacy of drugs requiring acid for absorption (ketoconazole, itraconazole, iron). Methotrexate clearance may be reduced, increasing toxicity risk. Esomeprazole can increase levels of some antiepileptics and antidepressants metabolised by CYP2C19.
Special Notes
PPIs should be prescribed at the lowest effective dose for the shortest necessary duration. The common practice of prescribing PPIs without clear indication or for indefinite periods is associated with unnecessary risk of long-term adverse effects. Gastroscopy to confirm diagnosis is recommended for uninvestigated symptoms in patients over 55. Magnesium levels should be checked before initiating long-term PPI therapy and monitored periodically. PPI use during pregnancy should be assessed individually; omeprazole has more safety data in pregnancy than esomeprazole. Rebound acid hypersecretion can occur after stopping PPIs, causing temporary worsening of symptoms.
Related Topics
Frequently Asked Questions
Why must esomeprazole be taken before eating?
Proton pumps are most active when stimulated by eating. Esomeprazole requires active proton pumps to be absorbed from its canalicular activation site and to bind to the enzyme. Taking it 30 to 60 minutes before a meal ensures maximum acid suppression during the meal when reflux and acid secretion are greatest. Taking it on a full stomach substantially reduces its efficacy.
What are the long-term risks of PPI use?
With long-term use (beyond eight weeks), clinically meaningful risks include: hypomagnesaemia (low magnesium, potentially causing severe cardiac arrhythmias and seizures), vitamin B12 deficiency, modest increase in bone fracture risk, increased susceptibility to C. difficile and other enteric infections, and community-acquired pneumonia. Regular review of the ongoing indication for PPI therapy is essential.
Can esomeprazole be taken with clopidogrel?
The combination is generally discouraged. Esomeprazole inhibits CYP2C19, the enzyme responsible for converting clopidogrel to its active antiplatelet form. This interaction reduces the antiplatelet effect and may increase the risk of cardiovascular events in patients requiring antiplatelet therapy. Pantoprazole has less CYP2C19 inhibitory activity and is the preferred PPI when a PPI is needed in patients on clopidogrel.
Sources
- EMA: Esomeprazole Summary of Product Characteristics 2023
- ESGE Guidelines: PPI Use in Gastrointestinal Disorders 2022
- Vaezi MF et al: Long-term PPI effects. Am J Gastroenterol 2023